TERT and DNMT1 express the sensitivity of predictive gliomas to Tesitham.

Decitabine (DAC) is a DNA methyl transferase inhibitor (DNA methyltransferase inhibitors, DNMTi) that reduces the expression of the mutant telomerease reversease (telomerase reversease, TERT) initiators.
clinical studies have shown that DAC has significant anti-tumor activity against isocric acid dehydrogenase 1 (IDH1) mutant gliomas.
But it's not entirely clear how DNMTi lowers the mechanism of TRT expression, and studies such as Jong-Whi Park of the Clinical Center for Neurology and Neuro-Oncology at the University Hospital of Heidelberg in Germany have studied the mechanisms and effects of DACs on gliomas, the results of which were published online in September 2020 in Neuro-Oncology.
study Methods The authors conducted in-body experimental studies of single DAC or in-body IDH1 mutant and wild glioma cell line in a single DAC or in union with telomerase inhibitors after regulating the expression and activity of TRT and DNMT1.
RNA sequencing and KEGG agglument analysis were used to evaluate the proliferation of tumor cells, and to analyze the sensitivity of TRT and DNMT1 expression to THEDH1 wild glioma's DAC response.
study tested four IDH1 R132H mutant glioma cell strains.
results showed that IDH1 mutant gliomas, which were missing from chromosome 1p/19q, were particularly sensitive to DAC and showed significant inhibition of DNA replication genes.
the transcription group showed that DAC could induce CDKN1A/p21 expression and TRT downgrading.
molecular changes have also been observed using amycin therapy to support the important mechanism by which DAC induces DNA damage.
knock-out p21 can lead to TTERT ups, while TRT overexploitation based on telomerase independent mechanism can improve DNST1 levels and DAC sensitivity.
addition, RNAi's targeting of the silent DNST1 gene inhibits DAC's sensitivity to TRT-mutated gliomas.
Conclusions The authors conclude that DAC reduces TERT expression through p21 protein, and that TERT and DNMT1 levels are potential determinants of the predictive response of glioma to DAC treatment.
, patients with gliomas with high expression TRT and DNMT1 can benefit from DAC.
: The intellectual property rights of the content published by the Brain Medical Exchange's Extra-God Information, God-based Information and Brain Medicine Consulting are owned by the Brain Medical Exchange and the organizers, the original authors and other relevant rights persons.
, editing, copying, cutting, recording, etc. without permission.
be used with a license, the source must also be indicated.
welcome to forward and share.
.